Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Ajugasterone C is a natural steroid compound mainly isolated from the plant Leuzea carthamoides. As a member of the degenerate steroid, muscosal herbal steroid C has attracted attention in traditional herbal medicine for its potential anti-inflammatory and metabolic regulatory effects. In recent years, with the deepening of research into the pharmacological activity and molecular mechanisms of natural products, osteosterone C has become a hot topic in metabolic and inflammation-related diseases due to its remarkable bioactivity and favorable safety profile. This paper will systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, and druggability evaluation of Muscosal Herbal Sterone C, exploring its potential for clinical application and future development directions.

Chemical structure and physicochemical properties

Musculoskeleton C has the molecular formula C27H40O8 and a molecular weight of 480.64, belonging to the ecdysteroid family. Its structural features include a typical tetracyclic steroid framework with multiple hydroxyl and ester group modifications, giving it high polarity. The LogP value is 0.15, indicating strong hydrophilicity and good water solubility. Its topological pole surface area (TPSA) is 130.64, and the number of hydrogen bond acceptors is 7, indicating that the molecule possesses strong hydrogen bond formation ability, which is significant for binding to biological targets. Musculoskeletol C does not easily cross the blood-brain barrier and shows no hepatotoxicity, cardiotoxicity, or hERG channel inhibitory activity, demonstrating good safety profiles.

Plant Origins and Extraction Methods

Leuzea carthamoides (Leuzea carthamoides), a perennial herbaceous plant of the Asteraceae family, are widely distributed in Siberia, Russia, and Central Asia. In traditional medicine, Jingu Cao is used as a herb to enhance physical strength, fight fatigue, and reduce inflammation. Osteosterone C, as one of its main active ingredients, is usually obtained through solvent extraction and chromatographic separation techniques.

Common extraction methods include:
1. Solvent extraction: Use polar organic solvents such as methanol, ethanol, or ethyl acetate to extract dry powder by reflux or ultrasound.
2. Liquid-liquid distribution: Uses solvents of different polarities to remove impurities and increase the content of target compounds.
3. Column chromatography separation: Separation and purification are performed using silica gel or C18 reversed phase columns, combined with high-performance liquid chromatography (HPLC) for component identification and purity testing.

In recent years, supercritical CO2 extraction and membrane separation technologies have also been attempted for the extraction of musculoskeletal sterone C, improving extraction efficiency and environmental friendliness.

Pharmacological activity research

Musculostosterone C exhibits multiple pharmacological activities, especially in anti-inflammatory and metabolic regulation.

Anti-inflammatory effects

In vivo experiments, tenoceal glucosterone C at 100 mg/kg showed significant inhibitory effects on the Sprague-Dawley rat pedema model induced by carrageen, indicating good anti-inflammatory effects. This anti-inflammatory activity may be related to its regulation of inflammatory mediator release and suppression of inflammatory signaling pathways.

Metabolic disease regulation

Musculoskeletin C regulates various metabolite-related targets, including AMPK (PRKAA1), PTPN1, STAT3, ABCB1, ALOX15, PRKCA, NFE2L2, SHBG, TOP1, and HIF1A. By activating the AMPK signaling pathway, musculoskeleton C can promote energy and lipid metabolism, improving insulin resistance. Its inhibitory effect on PTPN1 (protein tyrosine phosphatase 1B) helps enhance insulin signaling and lower blood sugar levels. Additionally, regulating the NFE2L2 (nuclear factor 2-related factor 2) pathway, Muscosethoxidone C can enhance cellular antioxidant capacity and reduce oxidative stress-related metabolic damage.

Other pharmacological activities

Musculoskeletin C may also participate in the regulation of inflammation and the tumor microenvironment by modulating transcription factors such as STAT3 and HIF1A, but related research is still in its early stages and requires further clarification.

Mechanism of action and molecular targets

The mechanism of action of musculoskeletal glucosterone C involves multiple signaling pathways and molecular targets, mainly including:

1. AMPK activation
   AMPK is a key regulator of cellular energy metabolism. Osteostisterone C activates AMPK, promotes fatty acid oxidation and glucose uptake, and improves metabolic disorders.

2. PTPN1 inhibition
   PTPN1 negatively regulates the insulin signaling pathway, and musculostosterone C enhances insulin sensitivity by inhibiting PTPN1 activity, improving abnormal glucose metabolism.

3. NFE2L2 regulation
   NFE2L2 is a core transcription factor for antioxidant stress. Muscosylsterone C activates the NFE2L2 pathway, enhancing cellular antioxidant defenses and reducing cellular damage caused by oxidative stress.

4. STAT3 and HIF1A regulation
   STAT3 and HIF1A are involved in inflammatory and cellular adaptive responses, and osteostisterone C may exert anti-inflammatory and cell-protective effects by regulating these transcription factors.

5. ABCB1 and TOP1 adjustments
   ABCB1 is a multidrug resistance-related protein, TOP1 is DNA topoisomerase, and the regulatory effect of musculostosterone C suggests its potential role in cell protection and drug metabolism.

Druggability evaluation and pharmacokinetics

The druggability parameters of musculostosterone C indicate that it has good potential for drug development. A molecular weight of 480.64 conforms to the Lipinski rule, and a LogP value of 0.15 indicates good water solubility, which is beneficial for oral absorption. Although higher TPSA (130.64) and hydrogen bond acceptor count (7) may limit membrane permeability, they also help form stable binding to targets.

In terms of safety, myosterone C showed no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, reducing the risk of cardiovascular adverse reactions. It cannot cross the blood-brain barrier, reducing the likelihood of central nervous system side effects. Ames mutagenicity test results are still unclear and require further testing.

In terms of pharmacokinetics, data on the absorption, distribution, metabolism, and excretion (ADME) of musculoskeleton C are currently limited. Preliminary studies suggest its oral bioavailability is limited, possibly related to its high polarity and metabolic stability. In the future, structural optimization and formulation improvements are needed to enhance its bioavailability.

Prospects and outlooks for clinical applications

Musculoskeletol C, as a natural steroid with multi-target regulatory capabilities, shows broad application prospects in metabolic diseases, inflammatory diseases, and related pathological conditions. Its anti-inflammatory effects offer new ideas for treating chronic inflammatory diseases, while its metabolic regulatory function is expected to be used as an adjunct treatment for metabolic syndromes such as diabetes, obesity, and fatty liver.

Future research should focus on the following directions:

1. In-depth analysis of mechanisms
   Using modern molecular biology techniques, the mechanism of musculoskeletal sterone C in cell signaling networks was further clarified, and its interaction patterns with key targets were clarified.

2. Pharmacokinetics optimization
   Through improvements in drug design and formulation technology, its oral bioavailability and in vivo stability are enhanced, enhancing clinical feasibility.

3. Safety and toxicological assessment
   Systematically conduct long-term toxicology and mutagenicity assessments to ensure clinical safety and lay the foundation for clinical trials.

4. Clinical research advances
   Based on existing pharmacological evidence, design a reasonable clinical trial protocol to verify efficacy and safety in patients with metabolic and inflammatory diseases.

Conclusion

Muscosal Glucosterone C, a degenerated steroid derived from Leuzea carthamoides, demonstrates promising drug development potential due to its significant anti-inflammatory and metabolic regulatory activities. Its multi-target mechanism of action and favorable safety profile provide a theoretical basis and practical basis for the treatment of metabolic and inflammation-related diseases. Although research on its pharmacokinetics and clinical applications is still insufficient, with advances in related technologies and deeper research, Muscosethoxolone C is expected to become an important research subject and potential drug candidate in the field of natural product pharmacology. Future multidisciplinary collaboration and systematic research will drive it from the laboratory to clinical practice, benefiting more patients.